Substituted 1-Benzyl-Cinnolin-4(1H)-one Derivatives for CB2 Receptor Selectivity

The patent applies local quality by introducing specific substituent groups at defined positions on the cinnoline core structure. Different substituents (R1, R2, R3 groups) are strategically placed to enhance CB2 receptor binding affinity while maintaining selective immunomodulatory activity. This localized modification of molecular structure allows the compounds to achieve both high specificity for CB2 receptors and effective modulation of immune responses.

The patent employs parameter changes by systematically varying the chemical substituents on the cinnoline scaffold. By changing the nature, position, and type of substituent groups (such as fluorine atoms, methoxy groups, and aromatic rings), the patent optimizes the balance between CB2 receptor affinity and immunomodulatory efficacy, resolving the contradiction between specificity and therapeutic versatility.

The patent applies segmentation by dividing the molecule into distinct functional domains: a core cinnoline scaffold providing structural stability, and variable substituent groups (R1, R2, R3) that can be independently optimized for CB2 receptor binding. This modular approach allows complex high-affinity compounds to be constructed from simpler, well-understood building blocks, managing molecular complexity while achieving high selectivity.

The patent uses composite material principles by combining the rigid cinnoline core with flexible aromatic and heteroatomic substituent groups. This composite structure creates molecules that can simultaneously achieve high CB2 receptor affinity through precise spatial arrangement and maintain manageable complexity through the use of common chemical building blocks with predictable properties.